(Circulation. 2004;110:e5-e6.)
© 2004 American Heart Association, Inc.
Images in Cardiovascular Medicine |
From the Institute Dante Pazzanese of Cardiology, São Paulo, Brazil (J.E.S., A.A., A.S., A.C.S., L.M.d.S., F.F., I.P., L.A.M.); University of FloridaShands, Jacksonville, Fla (M.A.C.); and Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC (A.F., R.V.).
Correspondence to J. Eduardo Sousa, MD, PhD, Ave Dr Dante Pazzanese 500, Ibirapuera, São Paulo, SP, Brazil, CEP 04012-909. E-mail jesousa{at}uol.com.br
A 60-year-old male patient with coronary disease was included in the "First-in Man" study1 and received a single sirolimus-eluting stent (SES, fast release) in December 1999 to treat a 90% diameter stenosis lesion located in the proximal right coronary artery (RCA). The patient had mild to moderate (<50% diameter stenosis) obstructions in the left anterior descending and left circumflex arteries. Coronary angiography and intravascular ultrasound (IVUS) revealed minimal neointimal growth in the midstent region at 4 months, 1 year, and 2 years after implantation. The patient underwent aortic and mitral valve replacement without complication 3 years after SES implantation. Left ventricle ejection fraction was 22%. He had a cardiac arrest out of the hospital in January 2004 (4-year follow-up). The patient was resuscitated but suffered severe cerebral damage. Postarrest angiography showed a widely patent SES in the RCA with a % obstruction volume of 19% by IVUS with minimal intimal hyperplasia by IVUS (Figure 1). The patient developed brain death and died. At necropsy, there was a 60% cross-sectional area of luminal narrowing of the RCA proximal to the stent. The stented segment was widely patent and well healed. Scanning electron microscopy of the proximal stent showed >95% of stent surface endothelialized (Figure 2). Light microscopic sections of the distal portion of the stent demonstrated a thin neointima consisting of smooth muscle cells and macrophages (predominately KP1-positive cells) in collagen-rich matrix. Approximately 75% of stent struts were covered by a thin type I collagen-rich neointima, and occasional calcific foci were present in neointima. The remaining 25% of struts were deeply embedded in the necrotic core of the plaque without associated inflammation. The RCA distal to stent was widely patent (<25% narrowing). The left anterior descending artery showed an acute plaque rupture and luminal thrombus in the proximal arterial segment. Atherosclerosis progression was noted in the left circumflex artery and posterior descending artery. The bioprosthetic aortic valve had a small fibrin thrombus deposition at the base of the right coronary cusp.
|
|
Footnotes
The editor of Images in Cardiovascular Medicine is Hugh A. McAllister, Jr, MD, Chief, Department of Pathology, St Lukes Episcopal Hospital and Texas Heart Institute, and Clinical Professor of Pathology, University of Texas Medical School and Baylor College of Medicine.
Circulation encourages readers to submit cardiovascular images to the Circulation Editorial Office, St Lukes Episcopal Hospital/Texas Heart Institute, 6720 Bertner Ave, MC1-267, Houston, TX 77030.
Reference
This article has been cited by other articles:
![]() |
T. Cyrus, H. Zhang, J. S. Allen, T. A. Williams, G. Hu, S. D. Caruthers, S. A. Wickline, and G. M. Lanza Intramural Delivery of Rapamycin With {alpha}v{beta}3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 820 - 826. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? Circulation, July 17, 2007; 116(3): 316 - 328. [Full Text] [PDF] |
||||
![]() |
A. V. Finn, M. Joner, G. Nakazawa, F. Kolodgie, J. Newell, M. C. John, H. K. Gold, and R. Virmani Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization Circulation, May 8, 2007; 115(18): 2435 - 2441. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Matsumoto, J. Shite, T. Shinke, H. Otake, Y. Tanino, D. Ogasawara, T. Sawada, O. L. Paredes, K.-i. Hirata, and M. Yokoyama Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography Eur. Heart J., April 2, 2007; 28(8): 961 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF] |
||||
![]() |
M. Joner, A. V. Finn, A. Farb, E. K. Mont, F. D. Kolodgie, E. Ladich, R. Kutys, K. Skorija, H. K. Gold, and R. Virmani Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk J. Am. Coll. Cardiol., July 4, 2006; 48(1): 193 - 202. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fishbein, I. S. Alferiev, O. Nyanguile, R. Gaster, J. M. Vohs, G. S. Wong, H. Felderman, I-W. Chen, H. Choi, R. L. Wilensky, et al. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents PNAS, January 3, 2006; 103(1): 159 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Aoki, A. C. Abizaid, P. W. Serruys, A. T.L. Ong, E. Boersma, J. E. Sousa, and N. Bruining Evaluation of Four-Year Coronary Artery Response After Sirolimus-Eluting Stent Implantation Using Serial Quantitative Intravascular Ultrasound and Computer-Assisted Grayscale Value Analysis for Plaque Composition in Event-Free Patients J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1670 - 1676. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Togni, S. Windecker, R. Cocchia, P. Wenaweser, S. Cook, M. Billinger, B. Meier, and O. M. Hess Sirolimus-Eluting Stents Associated With Paradoxic Coronary Vasoconstriction J. Am. Coll. Cardiol., July 19, 2005; 46(2): 231 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Finn, F. D. Kolodgie, J. Harnek, L.J. Guerrero, E. Acampado, K. Tefera, K. Skorija, D. K. Weber, H. K. Gold, and R. Virmani Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents Circulation, July 12, 2005; 112(2): 270 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Sousa, M. A. Costa, A. Abizaid, F. Feres, A. C. Seixas, L. F. Tanajura, L. A. Mattos, R. Falotico, J. Jaeger, J. J. Popma, et al. Four-Year Angiographic and Intravascular Ultrasound Follow-Up of Patients Treated With Sirolimus-Eluting Stents Circulation, May 10, 2005; 111(18): 2326 - 2329. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |